Suppr超能文献

鉴定 ALK 和 LTK-Ligand 2(增强子-α)的生物活性片段。

Identification of a biologically active fragment of ALK and LTK-Ligand 2 (augmentor-α).

机构信息

Department of Pharmacology, Yale School of Medicine, New Haven, CT 06520;

Department of Pharmacology, Yale School of Medicine, New Haven, CT 06520.

出版信息

Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):8340-8345. doi: 10.1073/pnas.1807881115. Epub 2018 Jul 30.

Abstract

Elucidating the physiological roles and modes of action of the recently discovered ligands (designated ALKAL1,2 or AUG-α,β) of the receptor tyrosine kinases Anaplastic Lymphoma Kinase (ALK) and Leukocyte Tyrosine Kinase (LTK) has been limited by difficulties in producing sufficient amounts of the two ligands and their poor stability. Here we describe procedures for expression and purification of AUG-α and a deletion mutant lacking the N-terminal variable region. Detailed biochemical characterization of AUG-α by mass spectrometry shows that the four conserved cysteines located in the augmentor domain (AD) form two intramolecular disulfide bridges while a fifth, primate-specific cysteine located in the N-terminal variable region mediates dimerization through formation of a disulfide bridge between two AUG-α molecules. In contrast to AUG-α, the capacity of AUG-α AD to undergo dimerization is strongly compromised. However, full-length AUG-α and the AUG-α AD deletion mutant stimulate similar tyrosine phosphorylation of cells expressing either ALK or LTK. Both AUG-α and AUG-α AD also stimulate a similar profile of MAP kinase response in L6 cells and colony formation in soft agar by autocrine stimulation of NIH 3T3 cells expressing ALK. Moreover, both AUG-α and AUG-α AD stimulate neuronal differentiation of human neuroblastoma NB1 and PC12 cells in a similar dose-dependent manner. Taken together, these experiments show that deletion of the N-terminal variable region minimally affects the activity of AUG-α toward LTK or ALK stimulation in cultured cells. Reduced dimerization might be compensated by high local concentration of AUG-α AD bound to ALK at the cell membrane and by potential ligand-induced receptor-receptor interactions.

摘要

阐明受体酪氨酸激酶间变性淋巴瘤激酶(ALK)和白细胞酪氨酸激酶(LTK)的最近发现的配体(命名为 ALKAL1、2 或 AUG-α、β)的生理作用和作用模式受到生产足够数量的两种配体及其稳定性差的限制。在这里,我们描述了 AUG-α 和缺失 N 端可变区的缺失突变体的表达和纯化程序。通过质谱对 AUG-α 的详细生化特性进行分析表明,位于增强子结构域(AD)中的四个保守半胱氨酸形成两个分子内二硫键,而位于 N 端可变区的第五个、灵长类特异性半胱氨酸通过形成二硫键介导两个 AUG-α 分子的二聚化。与 AUG-α 相反,AUG-α AD 发生二聚化的能力受到严重损害。然而,全长 AUG-α 和 AUG-α AD 缺失突变体均能刺激表达 ALK 或 LTK 的细胞发生类似的酪氨酸磷酸化。AUG-α 和 AUG-α AD 均可刺激 L6 细胞中的 MAP 激酶反应和 NIH 3T3 细胞中通过自分泌刺激表达 ALK 的细胞形成软琼脂集落的类似特征。此外,AUG-α 和 AUG-α AD 均可以类似的剂量依赖性方式刺激人神经母细胞瘤 NB1 和 PC12 细胞的神经元分化。总之,这些实验表明,缺失 N 端可变区对 AUG-α 在培养细胞中对 LTK 或 ALK 刺激的活性的影响最小。二聚化的减少可能通过与细胞膜上 ALK 结合的高浓度 AUG-α AD 得到补偿,也可能通过潜在的配体诱导的受体-受体相互作用得到补偿。

相似文献

1
8
A hypothalamic pathway for Augmentor α-controlled body weight regulation.增敏素 α 控制体重调节的下丘脑通路。
Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2200476119. doi: 10.1073/pnas.2200476119. Epub 2022 Apr 11.

引用本文的文献

4
A hypothalamic pathway for Augmentor α-controlled body weight regulation.增敏素 α 控制体重调节的下丘脑通路。
Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2200476119. doi: 10.1073/pnas.2200476119. Epub 2022 Apr 11.
5
Mechanism for the activation of the anaplastic lymphoma kinase receptor.间变性淋巴瘤激酶受体激活的机制。
Nature. 2021 Dec;600(7887):153-157. doi: 10.1038/s41586-021-04140-8. Epub 2021 Nov 24.
9
Receptor Tyrosine Kinase-Targeted Cancer Therapy.受体酪氨酸激酶靶向癌症治疗。
Int J Mol Sci. 2018 Nov 6;19(11):3491. doi: 10.3390/ijms19113491.

本文引用的文献

4
Adopting ALK and LTK.采用间变性淋巴瘤激酶(ALK)和白细胞酪氨酸激酶(LTK)。
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15783-4. doi: 10.1073/pnas.1521923113. Epub 2015 Dec 16.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验